Up a level |
Sharman, Jeff P, Coutre, Steven E, Furman, Richard R, Cheson, Bruce D, Pagel, John M, Hillmen, Peter, Barrientos, Jacqueline C, Zelenetz, Andrew D, Kipps, Thomas J, Flinn, Ian W et al (show 14 more authors)
(2019)
Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia.
Journal of Clinical Oncology, 37 (16).
pp. 1391-1402.
Rose-Zerilli, Matthew John Jerome, Parker, Helen, Larrayoz, Marta, Clifford, Ruth, Blakemore, Stuart, Edelmann, Jennifer, Gibson, Jane, Wang, Jun, Ljungstrom, Viktor, Chaplin, Tracy et al (show 26 more authors)
(2015)
Genomic Disruption of the Histone Methyltransferase SETD2 in Chronic Lymphocytic Leukemia.
, England.
Bloehdorn, Johannes, Braun, Andrejs, Taylor-Weiner, Amaro, Jebaraj, Billy Michael Chelliah, Robrecht, Sandra, Krzykalla, Julia, Pan, Heng, Giza, Adam, Akylzhanova, Gulnara, Holzmann, Karlheinz et al (show 24 more authors)
(2021)
Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia.
NATURE COMMUNICATIONS, 12 (1).
5395-.
Kreuzer, Karl-Anton, Furman, Richard R, Stilgenbauer, Stephan, Dubowy, Ronald L, Kim, Yeonhee, Munugalavadla, Veerendra, Lilienweiss, Esther, Reinhardt, Hans Christian, Cramer, Paula, Eichhorst, Barbara et al (show 4 more authors)
(2020)
The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab.
Leukemia, 34 (1).
pp. 296-300.